Eastern Bank Acquires 520 Shares of Novo Nordisk A/S (NYSE:NVO)

Eastern Bank boosted its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 0.6% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 90,450 shares of the company’s stock after buying an additional 520 shares during the period. Eastern Bank’s holdings in Novo Nordisk A/S were worth $7,781,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Natixis Advisors LLC boosted its stake in Novo Nordisk A/S by 2.7% during the third quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock valued at $366,125,000 after buying an additional 80,070 shares during the period. Norman Fields Gottscho Capital Management LLC lifted its stake in Novo Nordisk A/S by 45.3% during the fourth quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company’s stock worth $5,482,000 after purchasing an additional 19,870 shares during the last quarter. Versant Capital Management Inc bought a new stake in Novo Nordisk A/S during the fourth quarter worth about $86,000. Zions Bancorporation N.A. lifted its stake in Novo Nordisk A/S by 57.0% during the third quarter. Zions Bancorporation N.A. now owns 18,535 shares of the company’s stock worth $2,207,000 after purchasing an additional 6,726 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC lifted its stake in Novo Nordisk A/S by 14.8% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 289,438 shares of the company’s stock worth $34,463,000 after purchasing an additional 37,346 shares during the last quarter. Institutional investors own 11.54% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have issued reports on NVO shares. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. StockNews.com lowered Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. BMO Capital Markets dropped their price target on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, December 23rd. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. Finally, Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Novo Nordisk A/S presently has a consensus rating of “Buy” and an average price target of $140.20.

Novo Nordisk A/S Trading Down 2.5 %

NYSE:NVO traded down $2.13 during mid-day trading on Monday, reaching $84.13. 6,233,556 shares of the company’s stock traded hands, compared to its average volume of 7,230,714. Novo Nordisk A/S has a 12-month low of $81.50 and a 12-month high of $148.15. The firm has a market capitalization of $377.54 billion, a price-to-earnings ratio of 27.23, a PEG ratio of 1.37 and a beta of 0.45. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. The company has a 50 day moving average price of $100.35 and a 200-day moving average price of $119.04.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.